Abstract

Recombinant lentiviral vectors (LVs) are highly effective vaccination vehicles that elicit protective T cell immunity in disease models. Dendritic cells (DCs) acquire antigen at sites of vaccination and migrate to draining lymph nodes, where they prime vaccine-specific T cells. The potency with which LVs activate CD8+ T cell immunity has been attributed to the transduction of DCs at the immunization site and durable presentation of LV-encoded antigens. However, it is not known how LV-encoded antigens continue to be presented to T cells once directly transduced DCs have turned over. Here, we report that LV-encoded antigen is efficiently cross-presented by DCs in vitro. We have further exploited the temporal depletion of DCs in the murine CD11c.DTR (diphtheria toxin receptor) model to demonstrate that repopulating DCs that were absent at the time of immunization cross-present LV-encoded antigen to T cells in vivo. Indirect presentation of antigen from transduced cells by DCs is sufficient to prime functional effector T cells that control tumor growth. These data suggest that DCs cross-present immunogenic antigen from LV-transduced cells, thereby facilitating prolonged activation of T cells in the absence of circulating LV particles. These are findings that may impact on the future design of LV vaccination strategies.

Highlights

  • Lentiviral vectors (LVs) are efficient vaccination vehicles for the delivery of target antigens in vivo, and have been widely used as immunization vectors to activate protective T cell immunity in pre-clinical models of infectious disease and cancer.[1]

  • We have further exploited the temporal depletion of Dendritic cells (DCs) in the murine CD11c.DT receptor (DTR) model to demonstrate that repopulating DCs that were absent at the time of immunization cross-present lentiviral vectors (LVs)-encoded antigen to T cells in vivo

  • Cutaneous immunization with LVs results in the transduction of skin DCs that migrate to draining lymph nodes (LNs) and prime naive T cells,[11,14,15] and we have previously shown that DCs are required for presentation of LV-encoded antigens to CD8+ T cells in vivo.[16]

Read more

Summary

Introduction

Lentiviral vectors (LVs) are efficient vaccination vehicles for the delivery of target antigens in vivo, and have been widely used as immunization vectors to activate protective T cell immunity in pre-clinical models of infectious disease and cancer.[1]. We questioned how immunization with short-lived replication-incompetent viral particles could be reconciled with the long-term immunity elicited by LVs in vivo

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.